Patents by Inventor Eloise Hudry

Eloise Hudry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250001013
    Abstract: The disclosure provides compositions and methods for modulating transduction efficiency of AAV particles. Specifically, the disclosure provides AAV transduction modulators that modulate genes or gene products associated with AAV transduction efficiency in gene therapies.
    Type: Application
    Filed: November 23, 2022
    Publication date: January 2, 2025
    Inventors: Eloise Hudry, Katie Kubek-Luck, Keith Mansfield
  • Publication number: 20240209394
    Abstract: Described herein are capsid peptides that mediated efficient AAV transduction of the brain vasculature, mainly endothelial cells and pericytes, as well as smooth muscle cells, compositions (including AAV), and methods of using the same. Embodiments of the invention encompass AAV capsid proteins comprising an amino acid sequence that comprises at least four, at least five, or at least six contiguous amino acids from the sequence PRPPSTH (SEQ ID NO: 1); MAEPGAR (SEQ ID NO: 2); SQDPSTL (SEQ ID NO: 3); or MLYADNT (SEQ ID NO: 4).
    Type: Application
    Filed: April 27, 2022
    Publication date: June 27, 2024
    Inventors: Patricia L. Musolino, Casey A. Maguire, Eloise Hudry, Killian S. Hanlon
  • Publication number: 20170336395
    Abstract: The present disclosure provides methods of determining A-beta in a mammal before and after treatment of an amyloid disorder, comprising obtaining a first blood sample from the mammal; administering to the mammal a treatment for an amyloid disorder; obtaining a second blood sample from the mammal; quantifying a level of A-beta in the first blood sample and in the second blood sample; and determining the level of A-beta in the mammal before and after treatment of the amyloid disorder.
    Type: Application
    Filed: November 20, 2014
    Publication date: November 23, 2017
    Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE GENERAL HOSPITAL CORPORATION
    Inventors: Beverly L. Davidson, Bradley T. Hyman, Eloise Hudry
  • Patent number: 8198257
    Abstract: The invention relates to a viral vector for treating Alzheimers disease, which vector comprises a cholesterol 24-hydroxylase (CYP46A1) encoding nucleic acid. In a preferred embodiment, the viral vector may be an Adeno-Associated-Virus (AAV) vector, preferably an AVV5 vector. The vector may be useful for the manufacture of a pharmaceutical composition for the treatment of Alzheimers disease in a subject, wherein the vector is to be administered directly into the brain of the subject or by intravenous or intrathecal injection.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: June 12, 2012
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Patrick Aubourg, Nathalie Cartier-Lacave, Eloise Hudry
  • Publication number: 20110034540
    Abstract: The invention relates to a viral vector for treating Alzheimers disease, which vector comprises a cholesterol 24-hydroxylase (CYP46A1) encoding nucleic acid. In a preferred embodiment, the viral vector may be an Adeno-Associated-Virus (AAV) vector, preferably an AVV5 vector. The vector may be useful for the manufacture of a pharmaceutical composition for the treatment of Alzheimers disease in a subject, wherein the vector is to be administered directly into the brain of the subject or by intravenous or intrathecal injection.
    Type: Application
    Filed: September 11, 2008
    Publication date: February 10, 2011
    Applicant: Institut National De La Sante Et De La Recherche Medicale (Inserm)
    Inventors: Patrick Aubourg, Nathalie Cartier-Lacave, Eloise Hudry